Literature DB >> 2471698

A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas.

A Girling1, J Bartkova, J Burchell, S Gendler, C Gillett, J Taylor-Papadimitriou.   

Abstract

The monoclonal antibody (MAb) SM-3, which was raised to chemically deglycosylated milk mucin, reacts with an epitope present on the core protein of this mucin which we have referred to as PEM (polymorphic epithelial mucin). Although this mucin is abundantly expressed by both the lactating breast and breast carcinomas, the antibody SM-3 shows very little or no reactivity on the former but does react with 92% of breast carcinomas. Furthermore, SM-3 stains primary carcinomas of the lung, colon and ovary, but on the corresponding normal tissue the epitope is expressed at a much reduced level or not at all. These results indicate that an epitope masked in the normal mucin is exposed in the mucin produced by tumour cells, perhaps due to aberrant glycosylation. An extensive immunohistochemical study of other normal tissues reveals that the majority show only weak focal staining with SM-3 or none at all, the distal tubules and collecting ducts of the kidney, and sebaceous glands being the only normal tissues studied to show homogeneously positive staining.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471698     DOI: 10.1002/ijc.2910430620

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  69 in total

1.  Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.

Authors:  Philipp Beckhove; Rolf Warta; Britt Lemke; Diana Stoycheva; Frank Momburg; Martina Schnölzer; Uwe Warnken; Hubertus Schmitz-Winnenthal; Rezvan Ahmadi; Gerhard Dyckhoff; Mariana Bucur; Simone Jünger; Thomas Schueler; Volker Lennerz; Thomas Woelfel; Andreas Unterberg; Christel Herold-Mende
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

Review 3.  Nucleic acid aptamers: clinical applications and promising new horizons.

Authors:  X Ni; M Castanares; A Mukherjee; S E Lupold
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 4.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 5.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

Review 6.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

8.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

Review 9.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

10.  Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells.

Authors:  G Pecher; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.